Accurate risk stratification is critical for guiding treatment decisions in early breast cancer. We present an artificial intelligence (AI)-based tool that analyzes digitized tumor slides to predict 5-year metastasis-free survival (MFS) in patients w...
International journal of surgery (London, England)
May 1, 2025
BACKGROUND: Nonmetastatic castration-resistant prostate cancer (nmCRPC) is a clinical challenge due to the high progression rate to metastasis and mortality. To date, no prognostic model has been developed to predict the metastatic probability for nm...
Computer methods and programs in biomedicine
Apr 18, 2025
BACKGROUND AND OBJECTIVE: In search of a key driver for the invasive growth of cancer metastasis, AKT2 is found to be exceptionally expressed in colorectal cancer and its metastasis. Again, exceeding genomic arrangements of AKT2 can be held responsib...
BACKGROUND AND AIM: Colorectal cancer is among the most prevalent and deadliest cancers. Early prediction of metastasis in patients with colorectal cancer is crucial in preventing it from the advanced stages and enhancing the prognosis among these pa...
PURPOSE: Cetuximab (CET), targeting the epidermal growth factor receptor, is a systemic treatment option for patients with colorectal cancer. One known predictive factor for CET efficacy is the presence of CET-related rash; other putative toxicity fa...
BMC medical informatics and decision making
Apr 10, 2025
BACKGROUND: Analysis of Electronic Health Records (EHRs) is crucial in real-world evidence (RWE), especially in oncology, as it provides valuable insights into the complex nature of the disease. The implementation of advanced techniques for automated...
Muscle-Invasive Bladder Cancer (MIBC) is a more aggressive disease than non-muscle-invasive bladder cancer (NMIBC), with greater chances of metastasis. We sought to develop machine learning (ML) models to predict metastasis and prognosis in MIBC pati...
The Artificial Intelligence Patient Librarian (AIPL) was designed to meet the psychosocial and supportive care needs of Metastatic Breast Cancer (MBC) patients with HR+/HER2- subtypes. AIPL provides conversational patient education, answers user ques...
CDK4/6 inhibitors in combination with endocrine therapy are widely used to treat HR+/HER2- metastatic breast cancer leading to improved progression-free survival (PFS) compared to single agent endocrine therapy. Over 300 patients receiving standard-o...
More than 90% of deaths due to breast cancer (BC) are due to metastasis-related complications, with invasive ductal carcinoma (IDC) of the breast being the most common pathologic type of breast cancer and highly susceptible to metastasis to distant o...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.